VYEPTI is indicated for the preventive treatment of migraine in adults.
VYEPTI is indicated for the preventive treatment of migraine in adults.
""

Treatment experience

  • Suboptimal treatment response to a preventive, like an aCGRP
  • Insufficient reduction in migraine and headache frequency
""

Migraine symptoms

  • Severe headache pain
  • Experiencing sensitivity to light, sound, or movement
""

Emotional and life impact

  • Unable to fully engage at home, social, and work

* From a 2021 National Headache Foundation (NHF) survey of 1144 people with migraine attacks, of whom 898 had taken more than one preventive treatment. Regarding the statement, "Hopeful that the next preventive treatment would work," on a scale of 1-5 capturing how they felt (1 being not at all and 5 being exactly), 82% scored either a 4 or a 5.

aCGRP, anti-calcitonin gene-related peptide.

82%

of patients with migraine surveyed remained hopeful that the next preventive would work3*

2021 NHF Survey

Explore these 2 case studies from headache specialists Susan Hutchinson, MD, and Wade Cooper, DO, to see what a VYEPTI patient might look like in the real world.† Patient names and photos have been modified for privacy.

Patient Case: Derived from clinical practice data by DR SUSAN HUTCHINSON, MD, HEADACHE SPECIALIST

Her story
  • Valerie is a full-time teacher who has been coping with migraine for 8 years. It's hard for her to call in sick to work on short notice, and she frequently has to skip social events with friends.
Migraine history
  • Symptoms: Severe headache pain, nausea, vomiting, dizziness, and sensitivity to light and sound
  • Frequency: 12 migraine days/month
Unmet need
  • Frustrated and constantly worried about her next migraine attack
A patient like Valerie may be a candidate for VYEPTI
Previous treatment experience

Preventive: aCGRP

Acute: Triptan, high-dose NSAID​

Patient's treatment
goals

""
  • Reduce her migraine days per month
  • Reduce her headache pain severity
  • Reduce her migraine symptoms so she can fully engage in work and social activities

Patient Case: Derived from clinical practice data by DR Wade Cooper, DO, HEADACHE SPECIALIST

Her story
  • Ana is a full-time paralegal who has been coping with migraine for about 13 years. The pain is manageable, but the disruption to her life is not. Whether it’s canceling
    on friends or missing a milestone with her kids, each migraine attack feels like
    an unwelcome interruption.
Migraine history
  • Symptoms: Severe headache pain, neck pain, nausea, and vomiting
  • Frequency: 8 migraine days/month
Unmet need
  • Dissatisfied with her ability to fully participate in activities she loves
A patient like Ana may be a candidate for VYEPTI
Previous treatment experience

Preventive: aCGRP

Acute: Oral gepant​

OTC supplements: Magnesium

Alternative medicine: Massage therapy

Patient’s treatment
goals

  • Increase her monthly migraine-free days
  • Reduce her migraine symptom burden so she can enjoy more time with family

†Dr Hutchinson and Dr Cooper are paid consultants of Lundbeck.

""
IMPORTANT SAFETY INFORMATION AND INDICATION
CONTRAINDICATIONS

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI
in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI and institute appropriate therapy.

Constipation with Serious Complications: Constipation with serious complications has been reported following the use of monoclonal antibody CGRP antagonists, including VYEPTI, in the postmarketing setting. There were cases with monoclonal antibody CGRP antagonists that required hospitalization, including cases where surgery was necessary. In a majority of these cases, the onset of constipation was reported after the first dose; however, patients have also presented with constipation later on in treatment. The monoclonal antibody CGRP antagonist was discontinued in many of the reported cases of constipation with serious complications.

Monitor patients treated with VYEPTI for severe constipation and manage as clinically appropriate. The concurrent use of medications that reduce gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including VYEPTI, in the postmarketing setting. Some of the patients who developed new-onset hypertension had risk factors for hypertension. There were cases requiring initiation of pharmacological treatment for hypertension, and in some cases hospitalization. Hypertension may occur at any time during treatment, but was most frequently reported within 7 days of therapy initiation. The CGRP antagonist was discontinued in many of the reported cases.

Monitor patients treated with VYEPTI for new-onset hypertension or worsening of pre-existing hypertension, and consider whether discontinuation of VYEPTI is warranted if evaluation fails to establish an alternative etiology or blood pressure is inadequately controlled.

Raynaud’s Phenomenon: Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists. In reported cases with monoclonal antibody CGRP antagonists, symptom onset occurred a median of 71 days following dosing. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain. In most reported cases, discontinuation of the CGRP antagonist resulted in resolution of symptoms.

VYEPTI should be discontinued if signs or symptoms of Raynaud’s phenomenon develop, and patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud’s phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms.

ADVERSE REACTIONS

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

For more information, please see the Full Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION AND INDICATION
CONTRAINDICATIONS

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI
in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI and institute appropriate therapy.

Constipation with Serious Complications: Constipation with serious complications has been reported following the use of monoclonal antibody CGRP antagonists, including VYEPTI, in the postmarketing setting. There were cases with monoclonal antibody CGRP antagonists that required hospitalization, including cases where surgery was necessary. In a majority of these cases, the onset of constipation was reported after the first dose; however, patients have also presented with constipation later on in treatment. The monoclonal antibody CGRP antagonist was discontinued in many of the reported cases of constipation with serious complications.

Monitor patients treated with VYEPTI for severe constipation and manage as clinically appropriate. The concurrent use of medications that reduce gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including VYEPTI, in the postmarketing setting. Some of the patients who developed new-onset hypertension had risk factors for hypertension. There were cases requiring initiation of pharmacological treatment for hypertension, and in some cases hospitalization. Hypertension may occur at any time during treatment, but was most frequently reported within 7 days of therapy initiation. The CGRP antagonist was discontinued in many of the reported cases.

Monitor patients treated with VYEPTI for new-onset hypertension or worsening of pre-existing hypertension, and consider whether discontinuation of VYEPTI is warranted if evaluation fails to establish an alternative etiology or blood pressure is inadequately controlled.

Raynaud’s Phenomenon: Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists. In reported cases with monoclonal antibody CGRP antagonists, symptom onset occurred a median of 71 days following dosing. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain. In most reported cases, discontinuation of the CGRP antagonist resulted in resolution of symptoms.

VYEPTI should be discontinued if signs or symptoms of Raynaud’s phenomenon develop, and patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud’s phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms.

ADVERSE REACTIONS

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

For more information, please see the Full Prescribing Information and Patient Information.

References:

  1. Blumenfeld A, Ettrup A, Hirman J, Ebert B, Cady R. Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab. BMC Neurol. 2022;22(1):251.
  2. Kudrow D, Cady RK, Allan B, et al. Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurol. 2021;21(126):1-12.
  3. National Headache Foundation. Preventing migraine attacks: a current perspective. April 2021. Accessed May 25, 2023. https://headaches.org/wp-content/uploads/2021/05/NHF-Preventing-Migraine-Attacks-Report-Updated-Reference-2021MAY10.pdf